Page 5«..4567..1020..»

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Posted: May 19, 2025 at 2:44 am

Company intends to provide an interim read out by the end of summer 2025

Originally posted here:
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Posted in Global News Feed | Comments Off on Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

Posted: May 19, 2025 at 2:44 am

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-15 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders held on May 5, 2025. They granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.

See more here:
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

Posted in Global News Feed | Comments Off on Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform

Posted: May 19, 2025 at 2:44 am

WARSAW, Poland, May 16, 2025 (GLOBE NEWSWIRE) -- Member States are nearing the end of discussions on EU pharmaceutical reform to ensure affordable medicines and support EU manufacturing in Europe. This will enhance the Union’s strategic resilience and autonomy, promote economic growth, and strengthen the sustainability of national healthcare systems.

See the original post here:
Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform

Posted in Global News Feed | Comments Off on Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform

BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement

Posted: May 19, 2025 at 2:44 am

XI’AN, China, May 16, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced an exclusive cooperation agreement with Beijing Huahai Keyuan (Tech) Co., Ltd., a leading functional ingredient distributor in China. The term of the agreement is 36 months with a total contract value of 32 million US dollars. Pursuant to the agreement, Beijing Huahai Keyuan will serve as the exclusive sales partner of BON’s postbiotic hypoglycemic ingredients. BON aims to expand into the global blood sugar health market through the development of a series of innovative hypoglycemic solutions.

Read the original post:
BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement

Posted in Global News Feed | Comments Off on BON Announces The Launch Of Its Postbiotic Hypoglycemic Patented Ingredient Product Series And Its Cooperation Agreement

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the…

Posted: May 19, 2025 at 2:44 am

PALO ALTO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today presented the presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

Visit link:
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the...

Posted in Global News Feed | Comments Off on Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the…

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Posted: May 19, 2025 at 2:44 am

Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer on Wednesday, May 21st at 2:40 PM ET

Originally posted here:
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

Posted in Global News Feed | Comments Off on GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

Transactions of Managers and Closely Associated Persons

Posted: May 19, 2025 at 2:44 am

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 19,988 shares in Alvotech at USD 10.18 per share, by Richard Davies, Deputy Chairman of the Board of Directors Alvotech. The transaction is dated May 14, 2025.

See the original post here:
Transactions of Managers and Closely Associated Persons

Posted in Global News Feed | Comments Off on Transactions of Managers and Closely Associated Persons

BlueSphere Bio Appoints Alan Korman, Ph.D. as Chief Scientific Officer

Posted: May 19, 2025 at 2:44 am

Seasoned executive brings more than three decades of immunotherapy and drug discovery experience Seasoned executive brings more than three decades of immunotherapy and drug discovery experience

Original post:
BlueSphere Bio Appoints Alan Korman, Ph.D. as Chief Scientific Officer

Posted in Global News Feed | Comments Off on BlueSphere Bio Appoints Alan Korman, Ph.D. as Chief Scientific Officer

TestoPrime Reviews Side Effects (INVESTIGATED) Is This Testosterone Booster Safe? (Ingredients, Results & Where to Buy)

Posted: May 19, 2025 at 2:44 am

MIAMI, May 16, 2025 (GLOBE NEWSWIRE) -- Natural male health supplements often attract attention for their bold claims—offering simple and effective ways to regain lost energy, stamina, and youthful vitality. For many men in their 40s and 50s, declining testosterone levels can lead to fatigue, reduced muscle mass, and diminished performance.

More:
TestoPrime Reviews Side Effects (INVESTIGATED) Is This Testosterone Booster Safe? (Ingredients, Results & Where to Buy)

Posted in Global News Feed | Comments Off on TestoPrime Reviews Side Effects (INVESTIGATED) Is This Testosterone Booster Safe? (Ingredients, Results & Where to Buy)

75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition

Posted: May 19, 2025 at 2:44 am

Adam Koval?ík, 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world’s largest pre-college STEM competition in Columbus, Ohio

Continue reading here:
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition

Posted in Global News Feed | Comments Off on 75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition

Page 5«..4567..1020..»